Precision BioSciences, Inc.
Precision BioSciences, Inc. (DTIL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DTIL · as of Sep 30, 2025
Ownership Breakdown
54
Institutional Holders
▲ 3 vs Q2
$25.66M
Total Inst. Value
▲ $7.03M vs Q2
12.83M
Shares Outstanding
freeFloat 76.75%
4.65M
13F Shares Held
▲ 211,624 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DTIL largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLEICHROEDER LP biological products, (no diagnostic substances) | 1.07M | 9.73% | 9.73% | $5.93B | Nov 14, 2025 | — held |
LYNX1 CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 1.04M | 9.44% | 9.44% | $5.76B | Nov 13, 2025 | ▲ 6.5K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 653.6K | 5.92% | 5.92% | $3.61B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 492.6K | 4.46% | 4.46% | $2.72B | Nov 7, 2025 | ▲ 87.2K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 196.2K | 1.78% | 1.78% | $1.08B | Nov 13, 2025 | ▲ 115.9K |
BOOTHBAY FUND MANAGEMENT, LLC biological products, (no diagnostic substances) | 178.5K | 1.62% | 1.62% | $985.51M | Nov 14, 2025 | ▼ 21.5K |
ACADIAN ASSET MANAGEMENT LLC biological products, (no diagnostic substances) | 119.4K | 1.08% | 1.08% | $658.00M | Nov 13, 2025 | ▼ 106.6K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 109.5K | 99.15% | 99.15% | $604.60M | Nov 12, 2025 | ▲ 31.8K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 98.7K | 89.35% | 89.35% | $544.82M | Nov 12, 2025 | ▲ 41.2K |
TWO SIGMA INVESTMENTS, LP biological products, (no diagnostic substances) | 83.1K | 75.22% | 75.22% | $458.67M | Nov 14, 2025 | ▲ 66.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
14
Increased
+365.5K shares11
New Positions
first time holders9
Decreased
−260.2K shares0
Sold Out
fully exitedNet shares change (top 50)
+105.3K
+365.5K / −260.2K
Net new holders
+16
11 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DTIL insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
10
Buy transactions
5
Sell transactions
2.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Brown Melinda director | Jun 3, 2026 | Award | 20,979 | — | — | 21.0K | Form 4 ↗ |
Frankel Stanley director | Jun 3, 2026 | Award | 20,979 | — | — | 21.0K | Form 4 ↗ |
Germano Geno J director | Jun 3, 2026 | Award | 20,979 | — | — | 21.0K | Form 4 ↗ |
Pire Shari Lisa director | Jun 3, 2026 | Award | 20,979 | — | — | 21.0K | Form 4 ↗ |
Buehler Kevin director | Jun 3, 2026 | Award | 20,979 | — | — | 21.0K | Form 4 ↗ |
Amoroso Michael President and CEO | Feb 18, 2026 | Sale | 20,559 | $3.84 | $78.9K | 243.4K | Form 4 ↗ |
Kelly John Alexander Chief Financial Officer | Feb 18, 2026 | Sale | 8,149 | $3.84 | $31.3K | 125.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Precision BioSciences, Inc. (DTIL) is primarily owned by institutional investors, who hold approximately 36.2% of total shares outstanding. Company insiders own approximately 23.25%, while retail and public investors account for the remaining 40.50%.
The largest institutional shareholder of Precision BioSciences, Inc. is BLEICHROEDER LP, holding approximately 1.07 million shares — equal to 9.73% of outstanding shares — as of September 30, 2025.
A total of 54 institutional investors currently hold DTIL stock, with a combined institutional value of approximately $25,664,758 as of the most recent 13F filing period.
Frequently asked questions
DTIL ownershipPrecision BioSciences, Inc. (DTIL) is primarily owned by institutional investors, who hold approximately 36.2% of shares. The largest shareholder is BLEICHROEDER LP with a 9.73% stake. Company insiders hold 23.25%. Data sourced from SEC Form 13F as of September 30, 2025.